Methylphenidate Primed iTBS for Apathy in Neurocognitive Disorders
Status: Recruiting
Location: See location...
Intervention Type: Drug, Device
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Alzheimer's disease or mixed Alzheimer's disease and vascular disease
• MMSE score 10-28 inclusive
• Clinically significant apathy
• Stable dose of psychotropic medication
• Care partner must spend at least 10hrs/week with the participant
Locations
Other Locations
Canada
Sunnybrook Research Institute
RECRUITING
Toronto
Time Frame
Start Date: 2026-01
Estimated Completion Date: 2027-10-01
Participants
Target number of participants: 12
Treatments
Experimental: Methylphenidate + iTBS
Participants are currently receiving methylphenidate and receive iTBS in this study.
Experimental: iTBS only
iTBS only, no medication for apathy
Related Therapeutic Areas
Sponsors
Leads: Sunnybrook Health Sciences Centre
Collaborators: Sunnybrook Research Institute, Alzheimer Society of Canada, Brain Canada